Vertex Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Vertex Pharmaceuticals Inc 公司

公司简介

公司代码VRTX

公司名称Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

成立日期1989

CEODr. Reshma Kewalramani

员工数量6100

证券类型Ordinary Share

年结日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02210

电话16173416393

网址https://www.vrtx.com/

公司代码VRTX

上市日期Jul 24, 1991

成立日期1989

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.43K

--

Ms. Diana L. Mckenzie

Independent Director

1.47K

-10.17%

Mr. Michel Lagarde

Independent Director

1.13K

--

Ms. Kristen Ambrose

Senior Vice President, Chief Accounting Officer

--

名称

名称/职务

职务

持股

持股变动

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

收入明细

单位: USD更新时间: 3月5日周三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

地区USD

名称

营收

占比

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

7.99%

业务

地区

业务USD

名称

营收

占比

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

持股股东

股东统计

占比

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

股东类型

股东统计

占比

Investment Advisor

49.08%

Investment Advisor/Hedge Fund

37.63%

Pension Fund

2.66%

Research Firm

2.13%

Bank and Trust

1.87%

Hedge Fund

1.44%

Sovereign Wealth Fund

1.43%

Holding Company

0.19%

Individual Investor

0.12%

Other

3.41%

机构持股

更新时间: 1月19日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q1

2803

248.60M

96.81%

-2.22M

2024Q4

2877

248.75M

96.87%

-2.25M

2024Q3

2786

247.86M

96.18%

-4.19M

2024Q2

2747

248.35M

96.27%

-4.14M

2024Q1

2680

247.62M

95.87%

-4.47M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.88M

96.55%

-7.10M

2023Q1

2468

250.11M

97.13%

-4.73M

2022Q4

2454

248.59M

96.73%

-7.79M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Capital World Investors

28.32M

11.03%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.14M

9.01%

+102.47K

+0.44%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.32M

5.57%

-90.57K

-0.62%

Dec 31, 2024

State Street Global Advisors (US)

11.97M

4.66%

+163.15K

+1.38%

Dec 31, 2024

Capital Research Global Investors

10.42M

4.06%

+1.42M

+15.84%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.10M

3.54%

-1.25M

-12.06%

Dec 31, 2024

Wellington Management Company, LLP

5.91M

2.3%

+1.11M

+23.28%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.64M

2.19%

-287.65K

-4.84%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.22M

2.03%

+92.09K

+1.79%

Dec 31, 2024

JP Morgan Asset Management

4.61M

1.79%

-403.92K

-8.04%

Dec 31, 2024

持股ETF

更新时间: 19 小时前

机构名称

占比

Future Fund Active ETF

13.69%

VanEck Biotech ETF

11.53%

ProShares Ultra Nasdaq Biotechnology

8.36%

Invesco Nasdaq Biotechnology ETF

7.92%

Tema Neuroscience and Mental Health ETF

7.19%

iShares Biotechnology ETF

6.84%

Natixis Loomis Sayles Focused Growth ETF

5.03%

Franklin Genomic Advancements ETF

4.8%

Tema Cardiovascular and Metabolic ETF

4.37%

First Trust NYSE Arca Biotechnology Index Fund

3.64%

Future Fund Active ETF

占比13.69%

VanEck Biotech ETF

占比11.53%

ProShares Ultra Nasdaq Biotechnology

占比8.36%

Invesco Nasdaq Biotechnology ETF

占比7.92%

Tema Neuroscience and Mental Health ETF

占比7.19%

iShares Biotechnology ETF

占比6.84%

Natixis Loomis Sayles Focused Growth ETF

占比5.03%

Franklin Genomic Advancements ETF

占比4.8%

Tema Cardiovascular and Metabolic ETF

占比4.37%

First Trust NYSE Arca Biotechnology Index Fund

占比3.64%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Vertex Pharmaceuticals Inc

484.205USD

Vertex Pharmaceuticals Inc

484.205

概览

公司